This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Hematology				
Hematological mobilization	CXC chemokine receptor 4 (CXCR4; NPY3R)	<p>Studies in mice and in nonhuman primates suggest that the pepducin-based CXCR4 agonist ATI-2341 could help mobilize cell populations for bone marrow transplants. In normal mice and nonhuman primates, ATI-2341 caused a dose-dependent increase in circulating levels of polymorphonuclear neutrophils and hematopoietic stem and progenitor cells compared with vehicle or a pepducin control. Next steps include optimizing the CXCR4 agonist pepducins and selecting a development candidate.</p> <p>ATI-2341, a CXCR4 agonist from Anchor Therapeutics Inc., is in preclinical development for hematological mobilization. Mozobil plerixafor (AMD3100), a CXCR4 antagonist from Genzyme Corp., is approved in the U.S. to mobilize stem cells for transplant in non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) patients.</p> <p>SciBX 4(1); doi:10.1038/scibx.2011.12 Published online Jan. 6, 2011</p>	<p>Multiple patent applications filed; available for licensing Contact: Frederick Jones, Anchor Therapeutics Inc., Cambridge, Mass. e-mail: rjones@anchortx.com</p>	<p>Tchernychev, B. <i>et al.</i> <i>Proc. Natl. Acad. Sci. USA</i>; published online Dec. 6, 2010; doi:10.1073/pnas.1009633108 Contact: Stephen Hunt III, Anchor Therapeutics Inc., Cambridge, Mass. e-mail: shunt@anchortx.com Contact: Thomas P. Sakmar, The Rockefeller University, New York, N.Y. e-mail: sakmar@rockefeller.edu</p>